Why Didn’t IV Arginine Improve Acute Sickle Cell Pain? STArT Trial Investigator Explains

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 Sickle Cell Disease Treatment With Arginine Therapy (STArT) trial, discussed why intravenous arginine did not significantly improve time to crisis resolution among children and young adults hospitalized with acute sickle cell pain.

Although earlier phase 2 studies suggested reductions in opioid use and hospital length of stay, STArT found no significant improvement in its primary or secondary outcomes and was stopped early for futility.

Morris emphasized that the findings demonstrate that arginine did not improve the trial’s selected primary end point, but they also expose limitations in how acute sickle cell pain studies measure treatment benefit. Time to crisis resolution was defined as the interval between study-drug administration and the final intravenous opioid dose. However, patients may leave the hospital with substantial pain after transitioning to oral therapy, making “crisis resolution” a potentially misleading description.

Institutional practice also influenced the outcome. Across the 10 participating hospitals, median time to crisis resolution differed by as much as 114 hours, far exceeding the 17-hour treatment difference the trial was designed to detect. Modern hospital stays have also shortened since the assumptions informing the trial’s original power calculation were developed, leaving less time for an intervention to demonstrate an effect.

Patient heterogeneity created another challenge. Forty-one percent of participants met criteria for chronic pain, including one-third of children younger than 12 years, meaning not every episode may have reflected the same vaso-occlusive mechanism targeted by arginine. Morris also noted that patients who experienced pain at home for more than 24 hours had longer hospital stays, suggesting that earlier presentation and treatment could influence future outcomes. Together, these findings raise questions about whether current trial designs can adequately detect meaningful improvements in acute sickle cell pain.